Source comparison
AOD-9604 Pharmacokinetics: Circulation vs Biological Activity
The 30–60 minute plasma half-life of AOD-9604 represents the time required for serum concentration to drop by 50%. Not the duration of fat mobilisation effects. Once AOD-9604 binds to beta-3 adrenergic receptors on white adipose tissue, it initiates a phosphor
This comparison does not assign a generated winner or score.
- The 30–60 minute plasma half-life of AOD-9604 represents the time required for serum concentration to drop by 50%. Not the duration of fat mobilisation effects. Once AOD-9604 binds to beta-3 adrenergic receptors on white adipose tissue, it initiates a phosphorylation cascade involving protein kinase A (PKA) and hormone-sensitive lipase (HSL). That cascade persists for 2–4 hours after the peptide itself has cleared circulation, which is why researchers observe elevated free fatty acid levels in plasma samples taken 3 hours post-injection despite undetectable AOD-9604 concentrations.
- Subcutaneous administration. The standard route for AOD-9604. Produces peak plasma concentration (Cmax) at approximately 30–45 minutes post-injection. From that peak, concentration declines in a biphasic pattern: rapid initial drop (alpha phase, 30–60 min half-life), followed by slower terminal elimination (beta phase, approximately 90–120 min). The alpha phase reflects distribution from injection site into systemic circulation and initial receptor binding. The beta phase represents metabolic breakdown via peptidases in liver and kidney tissue. By the 6-hour mark, less than 3% of the administered dose remains detectable in serum. The compound is fully cleared.
- Compare that to longer-acting peptides like CJC-1295 (half-life 6–8 days) or even BPC-157 (4–6 hours), and AOD-9604's kinetic profile looks almost impractically short. But the lipolytic mechanism doesn't require sustained plasma levels. It requires transient receptor activation at the right metabolic moment. Research conducted at Monash University, where AOD-9604 was originally synthesised, demonstrated that single-dose administration produced measurable fat mass reduction over 12 weeks despite the peptide clearing within hours of each injection. The effect compounds across repeated doses because lipolysis. Once initiated. Doesn't reverse immediately when the peptide clears.